US0373261058
US0373261058
AN2 Therapeutics, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | -- | -- | -- |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| 38.109.000 | 54.554.000 | 30.1% | |
| Operating Income | -38.109.000 | -54.554.000 | 30.1% |
| Pretax Income | -35.174.000 | -51.321.000 | 31.5% |
| Net Income Common Stockholders | -35.174.000 | -51.321.000 | 31.5% |
| -- | -- | -- | |
| -- | -- | -- |